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Specific Antibody-Blocking Activities in Antilymphocyte Globulin as Correlates
of Efficacy for the Treatment of Aplastic Anemia
By Anajane G. Smith, Richard J. O’Reilly, John A. Hansen, and Paul J. Martin
Horse anti-human thoracic duct lymphocyte globulin
(ATDLG) has been used successfully for the treatment of
severe aplastic anemia. although not all lots have compara-
ble efficacy. We have characterized the antibody specifici-
ties contained in one lot of Swiss ATDLG found to provide a
response rate of 69% and another lot that provided only a
31 % response rate. Antibody specificities were analyzed
quantitatively by competitive inhibition assays with the use
of a panel of fluorescein-conjugated murine monoclonal
antibodies that recognize T cell antigens. common leuko-
cyte antigens. and “la-like” antigens. Although there was
wide variation in the amounts of individual antibody specifi-
I N 1983, the Aplastic Anemia Study Group reported
results of a prospective randomized trial that demon-
strated the utility of combination therapy with anti-human
thoracic duct lymphocyte globulin (ATDLG), HLA-haplo-
identical marrow, and androgens in patients with newly
diagnosed severe aplastic anemia.’ Twenty of 29 patients
(69%) treated with this regimen showed complete or partial
responses, compared to seven of 38 ( I 8%) concurrent and
historical controls who received androgens alone. A subse-
quent trial was designed to evaluate the role of HLA-
haploidentical marrow and androgens in patients receiving
ATDLG for treatment of aplastic anemia. The entry criteria
and dose schedule of ATDLG administration were the same
as for the first trial and the patient characteristics were
similar. The ATDLG for both trials was produced by the
Swiss Serum Institute, but a different lot was used for the
second trial. The administration of HLA-hapboidentical
marrow and androgens did not appear to influence the
response rate. However, only 1 1 of the 35 patients (31%)
entered into the second study had a response. (Full details of
this latter study will be reported elsewhere.) Since the
magnitude of the difference in response rates was too barge to
be explained by chance alone, we and others were bed to the
hypothesis that lot-to-lot variation in the ATDLG itself
accounted for the difference in response rates.2
The availability of two different lots of ATDLG, one of
proven efficacy and the other demonstrably less effective for
the treatment of severe aplastic anemia, made it possible to
test the hypothesis that ATDLG efficacy may be rebated to
antibody composition. It is possible that distinct antibody
specificities were responsible for the efficacy of the active lot
of ATDLG. Alternatively, distinct specificities might inhibit
the activity of functionally important antibodies in ATDLG.
We hypothesized that an analysis of antibody specificities
related to proven efficacy in the treatment of severe aplastic
anemia might prove useful in several ways. First, the data
could reveal something about the mechanism of effectiveness
of ATDLG. Second, the data might lead to the development
of a method for prospectively screening lots of ATDLG in
order to select those likely to be effective. Third, it might be
possible to identify one or a few monoclonal antibodies that
cities within each lot. the effective lot of ATDLG contained
an average of 21/2 times as much of each antibody specific-
ity as the less effective lot. There were only two antibody
specificities that differed remarkably from this pattern; and
these deviations did not appear sufficient to account for
the variation in ATDLG efficacy. It is possible that antibody
specificities other than those tested were responsible for
therapeutic efficacy. Alternatively, the data suggest that it
might be possible to achieve improved results for the
treatment of severe aplastic anemia with higher doses of
less effective lots of ATDLG.
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might provide a substitute for ATDLG in the treatment of
severe aplastic anemia.
MATERIALS AND METHODS
Isolation of cells. Mononuclear cells were isolated from the
blood of normal human volunteers by centnifugation over Ficoll-
1-lypaque (specific gravity, 1.077). T cells were enriched from
peripheral blood mononuclear cells (PBMCs) by removal of the
adherent non-T cell population on a nylon wool column. Granulo-
cytes were prepared by dextran sedimentation of the buffy coat from
the Ficoll-Hypaque bottom layer, followed by lysis of erythnocytes
with Tnis-buffered 0.83% NH4CI. Cells of the Burkitt’s B cell line
Daudi, positive for HLA class II (“la-like”) antigens, were main-
tamed under standard culture conditions.
Purification ofmonoclonal antibodies. Munine monoclonal lgG
antibodies were purified from ascites fluid by affinity chromatogna-
phy with the use of protein A-Sepharose (Phanmacia Fine Chemi-
cals, Piscataway, NJ).3 Munine monoclonal 1gM antibodies were
purified by dialysis against water.4 The precipitate was washed once
with water at pH 7.5 and then dissolved in phosphate-buffered saline
(PBS), pH 7.2. Antibody concentration was determined by Bradford
assay with the use of bovine IgG as a standard.5
Fluorescein conjugation of antibodies. Purified monoclonal
antibodies were dialyzed overnight against PBS, pH 7.2. Fluorescein
isothyocyanate (FITC) (Molecular Probes, Cave Junction, Ore) was
dissolved in 25 ￿L of dimethylsulfoxide and diluted to I mg/mi in
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0.286 mol/L of carbonate/bicarbonate buffer, pH 94#{149}6 FITC (0.25
mL) was mixed with purified antibody (I to 5 mg in I mi of PBS)
and incubated at 37 #{176}C. Aliquots of the mixture were removed at
intervals up to I 20 minutes and applied to a column of G25
Sephadex (Pharmacia) in order to separate conjugated antibody
from unneacted FITC.
Competitive inhibition assays. Cells (106 in 0.1 mi of RPMI
1640 containing 5% fetal calf serum and 3 mmol/L of EDTA) were
incubated for 30 minutes at 4 #{176}C with 25 ￿zL of serially diluted
ATDLG or purified monoclonal antibody in parallel assays. FITC-
conjugated antibodies were added at optimal concentration (twice
the amount required for saturation) without an intervening wash and
the incubation was continued for another 30 minutes at 4 #{176}C. Cells
were washed twice, resuspended in 0.5 mL of 0.85% saline contain-
ing 1% paraformaldehyde, and analyzed by flow microfluonimetry
(FACS IV, Becton Dickinson, Mountain View, Califl with bogarith-
mic amplification of the fluorescence signal. The modal fluorescence
intensity was determined according to a calibrated logarithmic scale
and expressed as a percentage of the control fluorescence of cells
stained in the absence of ATDLG with a correction for the
background fluorescence of cells stained in the presence of a 50- to
100-fold excess of the unconjugated monoclonal antibody.7 The
amount of ATDLG or monoclonal antibody required to block 50% of
the binding of each fluorescein-conjugated monoclonal antibody was
determined by semilog regression analysis and defined as 1 unit of
blocking activity. Results were expressed as the milligram equivalent
of monoclonal antibody contained in I .0 g of ATDLG. For example,
if I mg of ATDLG is determined to be the amount required to
produce 50% blocking ( 1 unit), then I g of ATDLG contains I ,000
units of blocking activity. If 1 zg of the monoclonal antibody also
inhibits binding by 50% (1 unit), then 1 g of ATDLG contains
blocking activity equivalent to 1 mg of the monoclonal activity.
RESULTS
The two lots of ATDLG contained equivalent amounts of
protein (67 mg/mL) as determined by Bradford assay, and
electrophoretic analysis demonstrated that both lots con-
tamed only gamma globulins. The antibody specificities in
each lot of ATDLG were analyzed quantitatively by compet-
itive inhibition assays with the use of a panel of fluorescein-
conjugated murine monoclonab antibodies that react with T
cells(35.1, 64.1, 66.1, 10.2, 12.1, 51.1), granulocytes and
monocytes (60.1, 60.3), or Ia-like antigens (p4.1, 7.2). For
each lot of ATDLG, there was wide variation in the amounts
of individual antibody specificities (Table 1). For example, 1
g of the effective ATDLG contained the equivalent of 48.7
mg of antibody 10.2 but only 0.1 mg of antibody 60.1.
Although it was determined that each lot of ATDLG con-
tamed the same amount of protein, the effective lot contained
an average of 2’/2 times as much of each antibody specificity
as the bess effective lot. Only two of the 1 1 tested antibodies
deviated remarkably from this pattern. At one extreme, the
effective lot contained 5’/2 times more CD5 activity than the
less effective lot. On the other hand, both lots contained
equivalent amounts of anti-T200 activity.
DISCUSSION
We have characterized some of the antibody specificities
contained in two lots of ATDLG, one of which was effective
for the treatment of severe apbastic anemia and the other of
which was less effective. Both lots contained antibody speci-
ficities that may have immunosuppressive effects.8’#{176} With
the exception of anti-CD5 and anti-T200, the two lots of
ATDLG had similar antibody specificity profiles. The inter-
pretation of these data is necessarily equivocal because of the
unexpected finding that, for most specificities, the effective
lot of ATDLG contained more than twice as much binding
activity as the less effective ATDLG. In this context, the
amount of anti-CD5 activity in the effective ATDLG was
only twice what otherwise might be expected and the amount
of anti-T200 activity was approximately 40% of the expected
value. It seems doubtful that single differences of this
magnitude can account for the variation in efficacy between
the two lots of ATDLG. It is possible that one or more
antibody specificities other than those tested were responsi-
ble for the efficacy of ATDLG in the treatment of severe
aplastic anemia. Alternatively, the data could suggest that if
antibody-binding activity is responsible for the efficacy of
ATDLG and assuming that certain other antibodies do not
exert inhibitory effects, then it might be possible to achieve
improved results with higher doses of less effective lots. The
Table 1 . Milligram Equivale nts of Monoclonal Anti bodies in One Gram of Antithoracic Du ct Lymphocyte Globulin
Monoclonal
Antigen
Mol Wt Cells
Mg Equivalent
Effective Ineffective
Antibody Specificity (kd) Tested ATDLG ATDLG Ratiot
35.1 CD2 50 TceIIs 0.52 0.19 2.7
64.1 CD3 19 TcelIs 0.72 0.38 1.9
66.1 CD4 55 TcelIs 0.84 0.58 1.5
10.2 CD5 67 TceIls 49 8.8 5.5
12.1 CD6 120 Tcells 27 9.4 2.9
51.1 CD8 32 Granulocytes 0.30 0.15 2.0
60. 1 CD1 1 95/1 50 Granulocytes 0. 10 0.03 3.3
60.3 CDw18 95/130/150 Granulocytes 0.85 0.40 2.1
9.4 T-200 200 T cells 0.42 0.43 1.0
p4. 1 DR 29/34 Daudi 1 .5 0.72 2.1
7.2 DR+DQ 29/34 Daudi 4.4 2.2 2.0
Mean 2.45
Cluster designations were defined in the First and Second International Workshops on Human Leucocyte Differentiation Antigens. See references 1 1
through 13 for descriptions of individual monoclonal antibodies and definitions of antigen specificities.
tEffective/ineffective ATDLG ratio.
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7. Remlinger K, Martin PJ, Hansen JA, Doney KC, Smith A, Verlag (in press)
toxicity of ATDLG, however, may preclude testing of this
hypothesis.
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